- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors
- Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
- Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
- Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
- Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
More ▼
Key statistics
On Monday, Summit Therapeutics Inc (SMMT:NMQ) closed at 9.96, -11.47% below its 52-week high of 11.25, set on May 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.89 |
---|---|
High | 10.09 |
Low | 8.80 |
Bid | 9.86 |
Offer | 9.95 |
Previous close | 8.79 |
Average volume | 2.23m |
---|---|
Shares outstanding | 701.98m |
Free float | 83.23m |
P/E (TTM) | -- |
Market cap | 6.54bn USD |
EPS (TTM) | -0.1657 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 21:00 BST.
More ▼